Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy

Sensitivity to androgen suppression therapy (AST) is a key determinant of survival in patients with nonlocalized prostate cancer. While an incomplete response to AST is associated with poor survival, additional therapy is typically withheld until obvious cancer progression. It is not known if the application of additional therapy earlier can have a favorable impact on long-term outcomes. We present the case of a patient with biochemically relapsed prostate cancer treated with early docetaxel after initial incomplete response to AST who now has a prolonged response to therapy.